Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
- Author
- COMI, G1 ; O'CONNOR, P2 ; MONTALBAN, X3 ; ANTEL, J4 ; RADUE, E.-W5 ; KARLSSON, G6 ; POHLMANN, H6 ; ARADHYE, S7 ; KAPPOS, L8
[1] Department of Neurology, Università Vita-Salute San Raffaele, Milan, Italy
[2] St Michael's Hospital, Toronto, ON, Canada
[3] Unitat de Neuroimmunologia Clinica, Vall d'Hebron University Hospital, Barcelona, Spain
[4] Montreal Neurological Institute, Montreal, QC, Canada
[5] MS MRI Evaluation Centre, University Hospital, Basel, Switzerland
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
[8] Neurology and Department of Biomedicine, University Hospital, Basel, Switzerland
FTY720D2201 Study Group - Source
Multiple sclerosis. 2010, Vol 16, Num 2, pp 197-207, 11 p ; ref : 19 ref
- Publisher
- Sage Publications, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- FTY720 Fingolimod MRI multiple sclerosis oral sphingosine I-phosphate
- Keyword (fr)
- Essai clinique phase II Fingolimod Imagerie RMN Maladie dégénérative Pathologie du système nerveux Phosphate Sclérose en plaques Voie orale Maladie inflammatoire Pathologie du système nerveux central
- Keyword (en)
- Phase II trial Fingolimod Nuclear magnetic resonance imaging Degenerative disease Nervous system diseases Phosphates Multiple sclerosis Oral administration Inflammatory disease Central nervous system disease
- Keyword (es)
- Ensayo clínico fase II Fingolimod Imaginería RMN Enfermedad degenerativa Sistema nervioso patología Fosfato Esclerosis en placa Vía oral Enfermedad inflamatoria Sistema nervosio central patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17F Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Neurology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22483199
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1177/1352458509357065 
https://dx.doi.org/10.1177/1352458509357065
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"197\";s:8:\"\u0000*\u0000epage\";s:3:\"207\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"COMI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"O'CONNOR, P\";i:1;s:12:\"MONTALBAN, X\";i:2;s:8:\"ANTEL, J\";i:3;s:11:\"RADUE, E.-W\";i:4;s:11:\"KARLSSON, G\";i:5;s:11:\"POHLMANN, H\";i:6;s:10:\"ARADHYE, S\";i:7;s:9:\"KAPPOS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Sage Publications\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"197\";s:8:\"\u0000*\u0000epage\";s:3:\"207\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"COMI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"O'CONNOR, P\";i:1;s:12:\"MONTALBAN, X\";i:2;s:8:\"ANTEL, J\";i:3;s:11:\"RADUE, E.-W\";i:4;s:11:\"KARLSSON, G\";i:5;s:11:\"POHLMANN, H\";i:6;s:10:\"ARADHYE, S\";i:7;s:9:\"KAPPOS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Sage Publications\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"197\";s:8:\"\u0000*\u0000epage\";s:3:\"207\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"COMI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"O'CONNOR, P\";i:1;s:12:\"MONTALBAN, X\";i:2;s:8:\"ANTEL, J\";i:3;s:11:\"RADUE, E.-W\";i:4;s:11:\"KARLSSON, G\";i:5;s:11:\"POHLMANN, H\";i:6;s:10:\"ARADHYE, S\";i:7;s:9:\"KAPPOS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Sage Publications\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"197\";s:8:\"\u0000*\u0000epage\";s:3:\"207\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"COMI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"O'CONNOR, P\";i:1;s:12:\"MONTALBAN, X\";i:2;s:8:\"ANTEL, J\";i:3;s:11:\"RADUE, E.-W\";i:4;s:11:\"KARLSSON, G\";i:5;s:11:\"POHLMANN, H\";i:6;s:10:\"ARADHYE, S\";i:7;s:9:\"KAPPOS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Sage Publications\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458509357065\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"16\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"197\";s:8:\"\u0000*\u0000epage\";s:3:\"207\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"COMI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:11:\"O'CONNOR, P\";i:1;s:12:\"MONTALBAN, X\";i:2;s:8:\"ANTEL, J\";i:3;s:11:\"RADUE, E.-W\";i:4;s:11:\"KARLSSON, G\";i:5;s:11:\"POHLMANN, H\";i:6;s:10:\"ARADHYE, S\";i:7;s:9:\"KAPPOS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:80:\"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Sage Publications\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
